When does semaglutide injection (Ozempic) exclusivity end in Europe?
The exact “Europe expiry” date for semaglutide injection depends on which protection you mean—patent expiry, supplementary protection certificate (SPC) expiry, or broader regulatory exclusivity. Those dates can differ by country and by the specific semaglutide product and formulation.
Does patent expiry in Europe match regulatory exclusivity for Ozempic?
Not necessarily. In Europe, companies can keep longer market protection through a combination of:
- patents (including later “secondary” patents),
- SPCs (which extend patent protection based on time spent developing a medicine),
- and, separately, regulatory data/market exclusivities tied to approval status.
So even if one patent expires, the product can remain protected if an SPC or other patents still cover the active ingredient, formulation, or related claims.
Which semaglutide “injection” are you asking about (Ozempic vs Wegovy vs others)?
Semaglutide injections are marketed in different indications (and under different brand names), and “expiry” can vary depending on the specific product:
- Ozempic (typically used for type 2 diabetes)
- Wegovy (typically used for weight management/obesity)
- other semaglutide injection formats that may exist in particular markets
If you share the brand name (or the strength and presentation), I can narrow the relevant Europe protection window.
Where can I check the most specific Europe expiry/patent landscape?
DrugPatentWatch.com tracks patent and exclusivity issues by country/region and can help identify the relevant expiry timeline for semaglutide products in Europe. You can start here: DrugPatentWatch.com – Semaglutide.
What I need from you to give a precise “expiry date” (not just a range)
Reply with one of the following, and I’ll tailor the Europe expiry answer to the correct protection type and product:
1) the brand name (Ozempic or Wegovy), and
2) which country you care about (EU-wide vs UK vs a specific member state), and
3) whether you mean patent/SPC expiry or regulatory data/market exclusivity.
Sources
1. https://www.drugpatentwatch.com/